Literature DB >> 29127560

Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy.

Robert O Cotes1, David R Goldsmith2, Sarah L Kopelovich3, Cathy A Lally4, Benjamin G Druss4.   

Abstract

Antipsychotic polypharmacy (APP) is a common strategy despite guidelines advising against this practice. This article seeks to quantify the prevalence and correlates of APP using Medicaid Analytic eXtract files from 2003 to 2004. Nineteen percent of Medicaid recipients who received an antipsychotic were treated with APP. Individuals who received APP were more likely to be white, male, disabled, between the ages of 18-29, diagnosed with a psychotic disorder, and diagnosed with a higher number of psychiatric conditions. Geographic variation in APP rates was also observed. Quality improvement initiatives may help reduce APP for medically vulnerable patients.

Entities:  

Keywords:  Antipsychotic polypharmacy; Geographic variation; Medicaid; Pharmacoepidemiology

Mesh:

Substances:

Year:  2017        PMID: 29127560      PMCID: PMC6427065          DOI: 10.1007/s10597-017-0183-y

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  66 in total

1.  Managed care: improving psychiatric drug benefit management: I. Lessons from Massachusetts.

Authors:  James E Sabin; Norman Daniels
Journal:  Psychiatr Serv       Date:  2003-07       Impact factor: 3.084

2.  Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.

Authors:  Benjamin Sneider; Sofie Gry Pristed; Christoph U Correll; Jimmi Nielsen
Journal:  Eur Neuropsychopharmacol       Date:  2015-05-07       Impact factor: 4.600

Review 3.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

4.  10-year trends in the treatment and outcomes of patients with first-episode schizophrenia.

Authors:  Jimmi Nielsen; P le Quach; C Emborg; L Foldager; C U Correll
Journal:  Acta Psychiatr Scand       Date:  2010-11       Impact factor: 6.392

5.  Relationships between medication treatments and neuropsychological test performance in schizophrenia.

Authors:  J A Sweeney; J G Keilp; G L Haas; J Hill; P J Weiden
Journal:  Psychiatry Res       Date:  1991-06       Impact factor: 3.222

6.  Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior.

Authors:  Christoph U Correll; Ladan Shaikh; Juan A Gallego; Jeffrey Nachbar; Vladimir Olshanskiy; Taishiro Kishimoto; John M Kane
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

7.  Geographic and clinical variation in clozapine use in the United States.

Authors:  T Scott Stroup; Tobias Gerhard; Stephen Crystal; Cecelia Huang; Mark Olfson
Journal:  Psychiatr Serv       Date:  2014-02-01       Impact factor: 3.084

8.  Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid.

Authors:  Seth A Seabury; Dana P Goldman; Iftekhar Kalsekar; John J Sheehan; Kimberly Laubmeier; Darius N Lakdawalla
Journal:  Am J Manag Care       Date:  2014-02-01       Impact factor: 2.229

9.  Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

Authors:  D V Jeste; M P Caligiuri; J S Paulsen; R K Heaton; J P Lacro; M J Harris; A Bailey; R L Fell; L A McAdams
Journal:  Arch Gen Psychiatry       Date:  1995-09

10.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

Authors:  Troy A Moore; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; Delbert G Robinson; Nina R Schooler; Steven P Shon; T Scott Stroup; Alexander L Miller
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384

View more
  4 in total

1.  Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients.

Authors:  Sermin Toto; Gudrun Hefner; Martina Hahn; Christoph Hiemke; Sibylle C Roll; Jan Wolff; Ansgar Klimke
Journal:  J Neural Transm (Vienna)       Date:  2021-01-13       Impact factor: 3.575

2.  Use of Academic Detailing With Audit and Feedback to Improve Antipsychotic Pharmacotherapy.

Authors:  Mary F Brunette; Robert O Cotes; Alexander de Nesnera; Gregory McHugo; Nino Dzebisashvili; Haiyi Xie; Stephen J Bartels
Journal:  Psychiatr Serv       Date:  2018-06-08       Impact factor: 3.084

3.  A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists.

Authors:  Robert O Cotes; A Umair Janjua; Beth Broussard; David Lazris; Ayesha Khan; Yunshen Jiao; Sarah L Kopelovich; David R Goldsmith
Journal:  Community Ment Health J       Date:  2021-05-29

4.  Cluster Analysis of Clozapine Consumer Perspectives and Comparison to Consumers on Other Antipsychotics.

Authors:  Sumeet Sharma; Sarah L Kopelovich; A Umair Janjua; Cristina Pritchett; Beth Broussard; Meena Dhir; Joseph G Wilson; David R Goldsmith; Robert O Cotes
Journal:  Schizophr Bull Open       Date:  2021-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.